Elizabeth R. Plimack, MD, MS

Articles by Elizabeth R. Plimack, MD, MS

Evolving Treatment Landscape of RCC: Future Directions in Care

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

September 12th 2023

Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.

Frontline IO-Based Regimens in Sarcomatoid or Rhabdoid Metastatic nccRCC

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

September 5th 2023

Centering discussion on sarcomatoid and rhabdoid non-clear cell renal cell carcinoma, panelists consider frontline IO-based regimens and their value in this setting.

Chromophobe RCC and Papillary Kidney Cancer: Novel Treatment Strategies

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

September 5th 2023

A brief discussion centered on optimal treatment strategies for patients with chromophobe or papillary kidney cancers.

Non-Clear Cell Renal Cell Carcinoma: Interpreting Data With IO/TKI Combination Therapies

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

August 29th 2023

Key opinion leaders in the field of renal cell carcinoma management reflect on recent data with IO/TKI combination therapy in patients with non-clear cell disease.

Updates from ASCO 2023: KEYNOTE-B61 Study in Non-Clear Cell Renal Cell Carcinoma

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

August 29th 2023

Switching its focus to non-clear cell RCC, the panel reviews data presented at ASCO 2023 on KEYNOTE-B61, combining lenvatinib + pembrolizumab in this setting.

Factors Aiding in the Selection of Frontline Therapy in Advanced Clear Cell RCC

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

August 22nd 2023

Panelists shed light on key factors that help to inform the selection of frontline therapy in patients with advanced clear cell renal cell carcinoma.

Selecting Frontline Therapy for Patients With Advanced Clear Cell RCC

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

August 22nd 2023

In the context of the available frontline treatment armamentarium for advanced clear cell RCC, key opinion leaders consider how they would select or sequence therapy.

Advanced Clear Cell RCC: Impact of the CLEAR Trial on Real-World Practice

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

August 15th 2023

Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice.

Data From KCRS 2023: The CLEAR and TRAVERSE Studies in Advanced Clear Cell RCC

ByBrian I. Rini, MD,Moshe Ornstein, MD, MA,Elizabeth R. Plimack, MD, MS,Robert J. Motzer, MD

August 15th 2023

Centering discussion on the KCRS 2023 annual meeting, experts in renal cell carcinoma elucidate data from the CLEAR and TRAVERSE studies in clear cell disease.

Elizabeth Plimack, MD, MS, on Depth of Response in from the KEYNOTE-426 Trial

ByElizabeth R. Plimack, MD, MS

June 28th 2020

Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC

ByElizabeth R. Plimack, MD, MS

June 9th 2020

Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426.